BAXTER HEALTHCARE S.A. Patent applications |
Patent application number | Title | Published |
20150238746 | FRANGIBLE CONNECTOR CLOSURE FOR TUBULAR CONNECTOR - A frangible connector closure is provided for connection to a medication administration tube, and includes a tubular body portion having an open end configured for being connected to a supply of medication, and an opposite closed end. An elongate, rigid frangible member is disposed at the closed end and closes the end from fluid flow. The frangible member has a closure end and an opposite free end, and a longitudinal axis. In addition, the frangible member extends in an axial direction and has a member transverse dimension. The free end forms a finger portion extending in the axial direction and has a transverse dimension less than the member transverse dimension. The closure end of the frangible member is readily separable from the body portion by manual manipulation relative to the body portion when the frangible member is disposed inside the tube, for user-activated opening of the connector. | 08-27-2015 |
20150219881 | OPTICAL IMAGING ASSEMBLY AND SYSTEM WITH OPTICAL DISTORTION CORRECTION - An optical imaging assembly is provided, having an optical axis, an object axis, a light-transmissive sleeve enclosing the object axis, being telecentric in object space, having at least three refractive lens elements, at least one of said elements having surfaces having at least one of cylindrical and acylindrical prescription, with an image plane, wherein the object being imaged lies within the sleeve. | 08-06-2015 |
20150104867 | ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS - The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes. | 04-16-2015 |
20150072414 | METHOD FOR PRODUCING CONTINUOUS CELL LINES - The present invention relates to a method for production of continuous cell lines comprising providing living cells of an animal or a human, irradiating said cells with UV light, proliferating said cells and selecting multiplying cells as cells of a continuous cell line. | 03-12-2015 |
20150033670 | METHOD AND APPARATUS FOR REMOVING AIR FROM AN ARTICLE-FILLED BAG WITH OSCILLATING RINGS - An apparatus is provided for removing air from a bag containing articles while the bag is traveling on a moving conveyor belt. A horizontal shaft is disposed in operational relationship to the conveyor belt. A plurality of rings is provided such that each ring has a thickness and a centered opening dimensioned to loosely accommodate the shaft, and also to rotationally oscillate relative to the shaft. Each ring is vertically displaceable relative to the shaft. Each ring independently generally follows a contour defined by the articles to expel air by downwardly depressing an outer surface of the bag under gravity caused by weight of each ring while the bag is carried on the conveyor belt below the rings. A radial distance between the shaft and the ring is greater than a diameter of the shaft. | 02-05-2015 |
20150024031 | Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent - Disclosed herein are methods and pharmaceutical compositions for reducing the pain associated with parenterally administering a therapeutic agent. The methods and compositions comprise a dispersion comprising microparticles of an analgesic agent in an amount effective to reduce the pain, inflammation, and/or immunological reaction associated with parenterally administering a primary therapeutic agent, wherein the microparticles of the analgesic agent have an effective particle size of less than 20 micrometers. | 01-22-2015 |
20150023978 | ANTI MIF ANTIBODIES - The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions. | 01-22-2015 |
20140364391 | Immobilization Of An Active Agent On A Substrate Using Compounds Including Trihydroxyphenyl Groups - The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, providing a substrate, contacting the substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated substrate, and contacting the trihydroxyphenyl-treated substrate with an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof. | 12-11-2014 |
20140336121 | FACTOR H FOR TREATMENT OF RHEUMATOID ARTHRITIS - The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising Factor H (FH). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the Factor H. | 11-13-2014 |
20140335113 | FACTOR H FOR TRANSPLANTATION - The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising Factor H (FH). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the Factor H. | 11-13-2014 |
20140329294 | CELL CULTURE MEDIUM FOR ADAMTS PROTEIN EXPRESSION - The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein. | 11-06-2014 |
20140328856 | TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G - The present invention provides, among other aspects, methods for the treatment of Alzheimer's disease in a subject in need thereof, the method including administration of a therapeutically effective amount of a pooled human immunoglobulin G (IgG) composition to a subject with moderately severe Alzheimer's disease, a subject carrying an ApoE4 allele, or both, where the amount of pooled human IgG is from 300 mg/kg to 800 mg/kg body weight of the subject per two week period, and where the amount is administered in one or more doses during the two week period after initiation of a therapeutic regimen. Also provided, are methods for selecting a treatment regimen for a subject with Alzheimer's disease, including diagnosing the severity of the Alzheimer's disease, determining if the subject carries an APOE4 allele, or both, and assigning a treatment regimen including administration of pooled human immunoglobulin G and/or an anti-beta amyloid monoclonal antibody. | 11-06-2014 |
20140328827 | Methods for Fucoidan Purification from Seaweed Extracts - Methods for purifying fucoidan in extracts from brown seaweed are disclosed. In particular, methods of purifying fucoidan in the extract to remove heavy metal ions, bacterial and endotoxin contaminants, and other impurities are disclosed. The methods include the use of a chelating agent, selective precipitation, and filtration. | 11-06-2014 |
20140294794 | METHODS FOR TREATING BLEEDING DISORDERS USING A PLATELET SUBPOPULATION - The present invention relates to a platelet subpopulation with high binding capacity to recombinant activated factor VII (rFVIIa), and its use for the treatment of bleeding disorders and for determining whether a subject is a candidate for treatment with rFVIIa. | 10-02-2014 |
20140287016 | IMMOBILIZATION OF AN ACTIVE AGENT ON A SUBSTRATE - The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, depositing a primer compound on a substrate, thereby forming a primed substrate, contacting the primed substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated primed substrate, and contacting the trihydroxyphenyl-treated primed substrate with a solution of an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the primed substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof. | 09-25-2014 |
20140276564 | PUMP CONTROLLER AND PUMP FOR INDIVIDUALIZED HEALTHCARE USE - According to an aspect of the present disclosure, a pump system for individualized healthcare use includes an infusion pump, a display, an input interface, and a pump controller. The pump controller is associated with a memory in which a closed set of predefined infusion therapies and a personalized identifier associated with an individual patient are stored. The pump controller is programmed to display the personalized identifier; to operate according to a first operational state, wherein the pump controller receives an input via the input interface, selects a predefined infusion therapy according to the input received, and controls the infusion pump to provide the selected predefined infusion therapy; to operate according to a second operational state; and to receive an operational state code via the input interface, and to change from the first to the second operational state only when the operational state code is received. | 09-18-2014 |
20140276528 | DIALYSIS BAG WITH ANTI-OCCLUSION FEATURE - A dialysis bag is provided, including a first layer of film and a second layer of film each having a closed end and an opposite outlet end, the layers sealed together about corresponding peripheral edges to define a bag chamber. An outlet assembly is sealingly disposed at the corresponding outlet ends and has a tubular administrative outlet with an inlet and is in fluid communication with the bag chamber. A dimple is formed in at least one of the layers adjacent to the inlet for preventing occlusion as a fluid level decreases in the bag. | 09-18-2014 |
20140276376 | SYSTEM AND METHOD FOR PERFORMING ALTERNATIVE AND SEQUENTIAL BLOOD AND PERITONEAL DIALYSIS MODALITIES - A dialysis system includes: a dialysis fluid pump receptacle actuated by a dialysis fluid pump actuator; a dialysis fluid line; a blood filter in fluid communication with the dialysis fluid pump receptacle via the dialysis fluid line; an extracorporeal circuit; a blood pump receptacle actuated by a blood pump actuator and in fluid communication with the blood filter via the extracorporeal circuit; and a control unit that (i) in a first treatment pumps peritoneal dialysis fluid through the dialysis fluid pump receptacle, the dialysis fluid line, the blood filter, the extracorporeal circuit and the blood pump receptacle to the patient's peritoneum operating the dialysis fluid pump actuator and the blood pump actuator at a first pressure, and (ii) in a second treatment pumps blood through the extracorporeal circuit, the blood pump receptacle and the blood filter operating the blood pump actuator at a second, different pressure. | 09-18-2014 |
20140276375 | SYSTEM AND METHOD FOR REMOTE PERITONEAL DIALYSIS EXCHANGES - A system and method is provided to allow multiple patients to receive peritoneal dialysis treatment at a walk-in facility without having to keep fresh dialysis solution on hand themselves. The walk-in facility is enabled to receive a peritoneal dialysis prescription from a patient, verify the prescription, determine the appropriate treatment for the patient, provide the patient with the appropriate dialysis solution in the appropriate amount, and enable the patient to undergo a dialysis treatment at the facility. The walk-in facility can also be enabled to monitor the patient's home dialysis treatment and to adjust the patient's treatment at the facility accordingly. The facility can be enabled to produce dialysis solution on demand by manufacturing the solution from solution components according to a patient's prescription. Moreover, the facility can use a sorbent system to regenerate effluent dialysis solution into fresh dialysis solution. | 09-18-2014 |
20140276374 | SYSTEM AND METHOD FOR PERITONEAL DIALYSIS EXCHANGES HAVING REUSABLE FILL AND DRAIN CONTAINERS - A peritoneal dialysis system includes (i) a reusable fill container; (ii) a reusable drain container; and (iii) a reusable continuous ambulatory peritoneal dialysis (“CAPD”) set configured and arranged to be fluidly connected to at least one of the reusable fill container or the reusable drain container. | 09-18-2014 |
20140276373 | SYSTEM AND METHOD FOR PERITONEAL DIALYSIS EXCHANGES HAVING REUSABLE ENERGIZING UNIT - A peritoneal dialysis system includes (i) a fill container, and (ii) an energizing unit that removably accepts the fill container, the energizing unit including a sterilization source so configured and arranged relative to the fill container when accepted by the energizing unit to place fluid within the fill container in a physiologically safe condition for delivery to the peritoneal cavity of a patient. | 09-18-2014 |
20140275496 | ISOLATION OF FACTOR H FROM FRACTION I PASTE - Among other aspects, the present disclosure provides methods for preparing enriched compositions of plasma-derived Factor H from fractions formed during the manufacturing processes of established plasma-derived therapeutic compositions. Specifically, methods are provided for the isolation of Factor H from Fraction precipitates commonly discarded during the manufacture of commercial IgG therapeutics. Advantageously, the Factor H compositions prepared according to these methods have improved proteolytic profiles and reduced amidolytic activity. | 09-18-2014 |
20140275484 | METHOD FOR PRODUCING FACTOR H FROM A PLASMA PRECIPITATION FRACTION - The present disclosure provides, among other aspects, improved methods for the manufacture of Factor H compositions from plasma precipitation fractions. In some aspects, the methods include an improved process step for extracting Factor H from a plasma precipitate fraction with reduced co-extraction of amidolytic activities. In other aspects, the methods include a heat treatment step for reducing impurities, such as amidolytic enzymes, from a Factor H composition. In yet other aspects, the methods include improved anion exchange, heparin affinity, and/or mixed mode chromatographic enrichment of Factor H. In still other aspects, the improved methods include a combination of the individual improved process steps disclosed herein. | 09-18-2014 |
20140271679 | METHODS TO PRODUCE A HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN BRAIN DISEASE-RELATED NATURAL IGGS - The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-β, anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-β, anti-RAGE, and anti-α-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-β, anti-RAGE, and anti-α-synuclein antibodies), are also provided. | 09-18-2014 |
20140271669 | METHODS TO PRODUCE A HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN BRAIN DISEASE-RELATED NATURAL IGGS - The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), are also provided. | 09-18-2014 |
20140271611 | SUBCUTANEOUS ADMINISTRATION OF ADAMTS13 - This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein. | 09-18-2014 |
20140271608 | RESORPTION ENHANCERS AS ADDITIVES TO IMPROVE THE ORAL FORMULATION OF LOW MOLECULAR WEIGHT HEPARINS - Aspects of the invention include methods for treating or preventing a thromboembolic disease in a subject. In practicing methods according to certain embodiments, an amount of a low molecular weight heparin (LMWH) and a synergistically effective combination of two or more gastrointestinal epithelial barrier permeation enhancers is orally administered to a subject in a manner sufficient to treat the thromboembolic disease in the subject. Compositions and kits for practicing methods of the invention are also described. | 09-18-2014 |
20140267709 | DRIP CHAMBER WITH INTEGRATED OPTICS - A drip chamber for an infusion tube, including: a first end arranged to receive a drip tube; a second end including an exit port; at least one wall connecting the first and second ends; a space enclosed by the first and second ends and the at least one wall; and at least one lens integral to the at least one wall or directly fixed to the at least one wall. | 09-18-2014 |
20140257176 | PUMPING SYSTEMS FOR CASSETTE-BASED DIALYSIS - A dialysis machine includes: a hardware unit including at least one pump actuator, at least one valve actuator and a cassette interface, the cassette interface including: (i) a plate that abuts the cassette; (ii) at least one pump aperture defined by the plate; (iii) at least one pump head moveable out of and retractable into the at least one pump aperture to operate a pumping portion of the cassette; (iv) at least one valve aperture defined by the plate; (v) at least one valve apparatus moveable out of and retractable into the at least one valve aperture to operate a valve portion of the cassette; (vi) at least one sensor aperture defined by the plate; and (vii) at least one sensor located in the least one sensor aperture, the at least one sensor operable with a sensor portion of the cassette. | 09-11-2014 |
20140255440 | RECOMBINANT VIRAL VECTORS AND METHODS FOR INDUCING AN IMMUNE RESPONSE TO YELLOW FEVER VIRUS - The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to yellow fever virus. The invention provides recombinant viral vectors based on the non-replicating modified vaccinia virus Ankara or based on a D4R-defective vaccinia virus. When administered according to methods of the invention, the recombinant viral vectors induce a broad immune response to yellow fever virus and demonstrate an excellent safety profile. | 09-11-2014 |
20140251908 | DIALYSIS TREATMENT DEVICES FOR REMOVING UREA - Dialysis treatment devices and methods for removing urea from dialysis waste streams are provided. In a general embodiment, the present disclosure provides a dialysis treatment device including: 1) a first filter having a filtration membrane, 2) a urea removal unit having urease and in fluid communication with the first filter, and 3) a second filter having an ion rejection membrane and in fluid communication with the first filter and the urea removal unit. | 09-11-2014 |
20140242067 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY INTRANASAL ADMINISTRATION OF IMMUNOGLOBULIN G - The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided. | 08-28-2014 |
20140232029 | KIT FOR MEASURING THE THROMBIN GENERATION IN A SAMPLE OF A PATIENT'S BLOOD OR PLASMA - The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl | 08-21-2014 |
20140207057 | INFUSION PUMP AND METHOD TO ENHANCE LONG TERM MEDICATION DELIVERY ACCURACY - An infusion pump is provided for pumping fluid though an administration set at a constant flow rate. The pump includes a pumping mechanism for pumping fluid and operates at a pulse frequency, and a controller controls the pulse frequency. Additionally, the pump has one or more sensors configured for measuring at least one characteristic value relating to a status of the infusion pump. The controller is configured for causing the pumping mechanism to operate at a first pulse frequency, and the one or more sensors measure the characteristic value intermittently. When the measured characteristic value meets a threshold value, the controller causes the pumping mechanism to operate at a second pulse frequency different from the first pulse frequency. | 07-24-2014 |
20140190887 | SYSTEM AND METHOD TO EFFICIENTLY CLEAN A BLOOD FILTER - A method for cleaning a blood filter includes: (i) pumping a physiologically safe fluid back and fourth through the insides and/or the outsides of a plurality of hollow fiber membranes of the blood filter to remove or loosen blood residuals, such as blood clots, proteins and/or biological fluid; (ii) injecting air into the physiologically safe fluid to form an air/fluid mixture; (iii) pumping the air fluid mixture through the insides and/or outsides of the plurality of the hollow fiber membranes of the blood filter to further or remove or loosen blood residuals therefrom; and (iv) removing the air/physiologically safe fluid mixture along with the removed or loosened blood residuals to drain. | 07-10-2014 |
20140190035 | OPTIMIZATION OF NUCLEATION AND CRYSTALLIZATION FOR LYOPHILIZATION USING GAP FREEZING - This application discloses devices, articles, and methods useful for producing lyophilized cakes of solutes. The devices and articles provide for a method of freezing liquid solutions of the solute by the top and the bottom of the solution simultaneously. The as frozen solution then provides a lyophilized cake of the solutes with large and uniform pores. | 07-10-2014 |
20140186323 | FACTOR VIIA-POLYSIALIC ACID CONJUGATES HAVING PROLONGED IN VIVO HALF-LIFE - The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma. | 07-03-2014 |
20140178403 | METHOD OF INHIBITING BINDING OR ACTIVITY OF MIF BY ADMINISTERING A MIF ANTAGONIST - Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | 06-26-2014 |
20140178357 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS - The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions. | 06-26-2014 |
20140162045 | RADIATION STABILIZED PVC COMPOSITIONS, AND METHOD OF MAKING SAME - Disclosed are PVC compositions with enhanced color resistance to electromagnetic irradiation & shelf life color stability; gamma-irradiated PVC articles; methods of making the gamma-irradiated PVC articles; and compositions including PVC resins for making the gamma-irradiated PVC articles. | 06-12-2014 |
20140161738 | HEMOSTATIC FOAM - The invention discloses a pharmaceutical hemostatic liquid foam base preparation comprising albumin as foaming agent and a fibrinogen precipitating substance and optionally a coagulation inducing agent, wherein albumin as foaming agent is present in native form; a method for the production of a transient hemostatic liquid foam; the transient hemostatic liquid foam; and a kit for making the foam. | 06-12-2014 |
20140154709 | METHODS OF MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF - The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma. | 06-05-2014 |
20140154297 | ANTIMICROBIAL SUBSTRATES AND METHODS FOR PROCESSING THE SAME - Substrates having antimicrobial films or coatings adhered to a surface of the substrate and methods for replenishing the antimicrobial activity of films or coatings adhered to substrate surfaces are disclosed. The antimicrobial films and coatings comprise a strongly basic anion-exchange resin and an anion bound to the strongly basic anion-exchange resin, the anion being free of transition metals. The methods involve exposing a film or coating to an anion having antimicrobial activity, the anion being free of transition metals, and the film or coating comprising a strongly basic anion-exchange resin, thereby obtaining an antimicrobial film or coating comprising the anion bound to the strongly basic anion-exchange resin. | 06-05-2014 |
20140144940 | MIXING SYSTEM, KIT AND MIXER ADAPTER - A system includes a cylinder having a bore with a piston disposed therein, the piston moveable along the bore of the cylinder and having a passage therethrough. The system also includes a mixer disposed in the passage in the piston and including at least one porous mixing device, the at least one porous mixing device comprising a three-dimensional lattice defining a plurality of tortuous, interconnecting passages therethrough, and having physical characteristics to sufficiently mix the first and second components, which characteristics include a selected one or more of mean flow pore size, thickness and porosity. | 05-29-2014 |
20140141030 | CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of | 05-22-2014 |
20140141029 | CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of | 05-22-2014 |
20140130909 | INFUSION LINE MANAGEMENT SYSTEM - An infusion line management system is provided, including a label generating device receiving prescription information for one or more patient prescriptions, the received information being used to generate, for each of the one or more prescriptions, a label including a master label and one or more sub-labels related to the corresponding prescription; each master label includes at least information related to the prescription and an indicator identifying a particular portion of a patient infusion system to which the prescription should be connected; and the one or more sub-labels each include the indicator, the one or more sub-labels being individually removable from the master label and affixable to locations throughout the patient infusion system. | 05-15-2014 |
20140128445 | POLYMERIC BENZYL CARBONATE-DERIVATIVES - The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described. | 05-08-2014 |
20140121351 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE - The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst. | 05-01-2014 |
20140120078 | FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE - Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. | 05-01-2014 |
20140117116 | SPRAY HEAD FOR TWO COMPONENT MIXER - A device for mixing at least two separate streams of components which, when mixed, form a combined fluid stream. The device comprises a conduit with at least two separate passageways leading to exit openings at an end face of the conduit. Each passageway communicates with a separate component stream and is arranged to direct the separate component stream in a downstream direction. The exit openings each have a predetermined cross-sectional flow area. A separate channel is located at a downstream end of each passageway exit opening The channels are arranged to redirect the flow from each passageway to an axial direction. A single mixing chamber communicates with all of the separate channels, the mixing chamber being arranged to receive each of the component streams at an upstream end thereof and to permit a mixing of the component streams. An outlet is arranged downstream of the mixing chamber through which the combined fluid stream is dispensed. | 05-01-2014 |
20140114276 | RECONSTITUTION AND APPLICATOR SYSTEM FOR WOUND SEALANT PRODUCT - A system for mixing or reconstituting agents including engageable syringe barrels, one of which having a male engagement region and the other a female engagement region. Each of the male and female engagement regions is provided with a screen. The screens are closely spaced from one another when the first and second syringe barrels are engaged with one another. The screens may take the form of a mesh, a plurality of protuberances, or cantilevered wedges having tapering thicknesses. | 04-24-2014 |
20140110341 | INTEGRATED WATER TESTING SYSTEM AND METHOD FOR ULTRA-LOW TOTAL CHLORINE DETECTION - A system and method for determining a concentration of total chlorine in dialysis water are provided. The system comprises a main unit housing an iodide/water sample chamber and a reducing agent chamber. An electrode pair bridges the two chambers and generates tri-iodide proportional to the amount of total chlorine in the dialysis water. The electrode pair detects the amount of tri-iodide generated in proportion to the amount of active chloride in the dialysis water. The system is suitable for use in connection with, or for incorporation into, a water purification system for generating dialysis fluid, and may include a display that alerts the user to stop or prevent a hemodialysis treatment if the total chlorine level exceeds a predetermined level. | 04-24-2014 |
20140110340 | TOTAL CHLORINE WATER DETECTION SYSTEM AND METHOD FOR MEDICAL FLUID TREATMENTS - A system and method for determining a concentration of total chlorine in dialysis water are provided. The system comprises a main unit housing a KI/water sample chamber and a sodium sulfate chamber. A first electrode pair bridges the two chambers and generates tri-iodide proportional to the amount of total chlorine in the water sample. A second electrode pair in contact with fluid in the KI/water sample detects an amount of tri-iodide generated by the first electrode pair. The system is suitable for use in connection with, or for incorporation into, a water purification system for generating dialysis fluid, and may include a display that alerts the user to stop or prevent a hemodialysis treatment if the total chlorine level exceeds a predetermined level. | 04-24-2014 |
20140107320 | BLOOD COAGULATION PROTEIN CONJUGATES - The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH | 04-17-2014 |
20140106453 | STIRRED TANK REACTOR SYSTEMS AND METHODS OF USE - A method of mixing a fluid includes positioning a flexible bag into the chamber of a support housing, the support housing having a plurality of baffles positioned so that the bag folds around the baffles. A fluid is delivered into a compartment of the flexible bag. A mixing element, such as an impeller, is moved within the compartment of the flexible bag so as to mix the fluid therein. | 04-17-2014 |
20140100548 | CATHETER/FISTULA NEEDLE TO BLOODLINE CONNECTION ASSURANCE DEVICE - In general, multiple embodiments of a catheter/fistula needle to bloodline connection assurance device, which secures and strengthens a connection between an extension tube end of a catheter or fistula needle and a bloodline, are provided. A first embodiment of the assurance device is configured for use with a bloodline connector having locking clips which are biased slightly outwardly from the bloodline connector. The first embodiment of the assurance device includes clamshell halves that open rotatably about at least one hinge. The first embodiment of the assurance device includes an upper, threaded portion and a lower housing portion. The interior wall of the upper portion defines a plurality of barbs configured to engage with distal or moveable ends of the locking clips. Each locking clip is biased slightly outwardly to enable the distal or moveable end of the locking clip to fit between two respective barbs. | 04-10-2014 |
20140100547 | CATHETER/FISTULA NEEDLE TO BLOODLINE CONNECTION ASSURANCE DEVICE - In general, multiple embodiments of a catheter/fistula needle to bloodline connection assurance device, which secures and strengthens a connection between an extension tube end of a catheter or fistula needle and a bloodline, are provided. In one embodiment, the assurance device includes a clamshell having two halves that open rotatably about at least one hinge. The assurance device includes a male luer portion that pressure seals to the male luer portion of the bloodline connector. The bloodline male luer portion of the device extends to a female luer portion, which is lined with a compressible material that conforms around any industrial catheter/fistula needle connector when the assurance device is closed about the mated connectors. Once the assurance device is closed, this prevents axial movement of the bloodline connector relative to the assurance device. | 04-10-2014 |
20140094775 | CATHETER/FISTULA NEEDLE TO BLOODLINE CONNECTION ASSURANCE DEVICE - In general, multiple embodiments of a catheter/fistula needle to bloodline connection assurance device, which secures and strengthens a connection between an extension tube end of a catheter or fistula needle and a bloodline, are provided. One embodiment includes internal and external clamshells. Internal clamshell halves pressure seal to the bloodline connector, and form outwardly extending barbs. The external clamshell opens rotatably about at least one hinge and includes inwardly facing threads that catch the outer barbs of the internal clamshell. After a user connects the catheter or fistula needle to the bloodline, the user closes the internal clamshell about the bloodline connector. Then, the user closes the external clamshell about the internal clamshell, causing the inwardly facing barbs of the external clamshell to engage the outwardly facing barbs of the internal clamshell. Such engagement prevents axial movement of the bloodline connector relative to the external clamshell. | 04-03-2014 |
20140094740 | DIALYSIS CONNECTOR AND CAP COMPATIBLE WITH GAS STERILIZATION - A dialysis disposable sterilization apparatus includes a connector and a protective cap fitted to the connector. The apparatus also includes a sealing ring provided by one of the protective cap or the connector, the sealing ring forming a seal between the cap and the connector, the seal capable of holding pressure. The apparatus further includes a stabilization rib provided by the connector, the stabilization rib positioned and arranged to (i) tend to prevent the protective cap from vibrating about the sealing ring and (ii) enable a sterilizing gas to flow past the stabilization rib to contact the sealing ring. | 04-03-2014 |
20140094739 | PUMPING SYSTEMS FOR CASSETTE-BASED DIALYSIS - A dialysis machine includes: a hardware unit including at least one pump actuator, at least one valve actuator and a cassette interface, the cassette interface including: (i) a plate that abuts the cassette; (ii) at least one pump aperture defined by the plate; (iii) at least one pump head moveable out of and retractable into the at least one pump aperture to operate a pumping portion of the cassette; (iv) at least one valve aperture defined by the plate; (v) at least one valve apparatus moveable out of and retractable into the at least one valve aperture to operate a valve portion of the cassette; (vi) at least one sensor aperture defined by the plate; and (vii) at least one sensor located in the least one sensor aperture, the at least one sensor operable with a sensor portion of the cassette. | 04-03-2014 |
20140094738 | PUMPING SYSTEMS FOR CASSETTE-BASED DIALYSIS - A dialysis machine includes: a hardware unit including at least one pump actuator, at least one valve actuator and a cassette interface, the cassette interface including: (i) a plate that abuts the cassette; (ii) at least one pump aperture defined by the plate; (iii) at least one pump head moveable out of and retractable into the at least one pump aperture to operate a pumping portion of the cassette; (iv) at least one valve aperture defined by the plate; (v) at least one valve apparatus moveable out of and retractable into the at least one valve aperture to operate a valve portion of the cassette; (vi) at least one sensor aperture defined by the plate; and (vii) at least one sensor located in the least one sensor aperture, the at least one sensor operable with a sensor portion of the cassette. | 04-03-2014 |
20140086898 | FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE - Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. | 03-27-2014 |
20140083944 | WEIGHT-CONTROLLED SORBENT SYSTEM FOR HEMODIALYSIS - A hemodialysis system including (i) a dialyzer, (ii) a blood circuit including a blood pump in fluid communication with the dialyzer, (iii) a dialysate circuit including a dialysate circulation pump in fluid communication with the dialyzer, the dialysate circuit further including a sorbent cartridge for cleaning used dialysate, (iv) a dialysate reservoir, (v) a reservoir pump in fluid communication with the dialysate circuit and the dialysate reservoir, (vi) a supply of concentrate for reconstituting dialysate in the dialysate circuit, and (vii) wherein the hemodialysis system is configured to electronically weigh the dialysate reservoir and the supply of concentrate. | 03-27-2014 |
20140081233 | INFUSION SYSTEM USING OPTICAL IMAGER FOR CONTROLLING FLOW AND METHOD THEREOF - A method of operating an infusion pump includes transmitting light through or around a drop of fluid suspended from an end of a drip tube for the infusion pump, the end of the drip tube located in a drip chamber for the infusion pump, wherein the drip tube is configured for connection to a source of the fluid; receiving, using an optical system for the pump, light transmitted through or around the drop; transmitting, to a specially programmed microprocessor and using the optical system, data regarding the received light; and, using the microprocessor to calculate a volume of the drop using the data. | 03-20-2014 |
20140074018 | METHOD OF PERFORMING PERITONEAL DIALYSIS USING PNEUMATIC VALVES - A method of performing peritoneal dialysis includes: (i) locating a supply of fresh dialysis fluid above a patient's peritoneal cavity; (ii) locating a drain or a drain container below the patient's peritoneal cavity; (iii) connecting a supply line to the supply of fresh dialysis fluid and the patient's peritoneal cavity; (iv) connecting a drain line to the patient's peritoneal cavity and the drain or drain container; (v) pneumatically opening a supply line valve during a fill cycle; (vi) gravity filling the patient's peritoneal cavity with the supply line valve open during the fill cycle; (vii) pneumatically opening a drain line valve during a drain cycle; and (viii) draining the patient's peritoneal cavity with the drain line valve open during the drain cycle. | 03-13-2014 |
20140072743 | POLYMER FILMS CONTAINING MICROSPHERES - Polymer films having hollow microspheres to simultaneously reduce the coefficient of friction and residue on ignition, and methods of making films and containers from the films. In a general embodiment, the present disclosure provides a film including at least one layer having hollow microspheres mixed within the layer. The microspheres can be in a concentration ranging from about 250 ppm to about 750 ppm within the layer. | 03-13-2014 |
20140072614 | RAPIDLY ACTING DRY SEALANT AND METHODS FOR USE AND MANUFACTURE - Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties. | 03-13-2014 |
20140067425 | PATIENT INFORMATION SOFTWARE SYSTEM INCLUDING INFUSION MAP - An infusion map system includes a memory storing at least infusion mapping instructions, and a processor that executes the stored instructions. When the processor executes the infusion mapping instructions, the infusion map system performs a displaying function that displays at least a portion of an electronic medical record associated with a patient and a diagramming function that receives the electronic medical record and generates an infusion map showing all intravenous drugs being administered to the patient. For each of the drugs, the infusion map further illustrates a route of administration for the drug. An order administering function performed by the system allows a user to alter the infusion map, and a record updating function of annotating the electronic medical record to correspond to the altered infusion map. | 03-06-2014 |
20140062996 | USER INTERFACE POWERED VIA AN INDUCTIVE COUPLING - A hinge is provided for mechanically and electrically coupling a machine and a display wirelessly. The hinge includes a machine portion having a first transceiver for wirelessly sending a signal concerning an operation or status of the machine and a display portion having a second transceiver for wirelessly receiving the operating signal. The hinge machine portion and the hinge display portion are mechanically connected so as to: (i) swivel with respect to each other; or (ii) tilt with respect to each other. | 03-06-2014 |
20140051094 | Method and Compositions for Specifically Detecting Physiologically Acceptable Polymer Molecules - The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition. | 02-20-2014 |
20140050759 | RECOMBINANT VIRAL VECTORS AND METHODS FOR INDUCING A HETEROSUBTYPIC IMMUNE RESPONSE TO INFLUENZA A VIRUSES - The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses. | 02-20-2014 |
20140045245 | REPLICATION DEFICIENT INFLUENZA VIRUS FOR THE EXPRESSION OF HETEROLOGOUS SEQUENCES - The present invention relates to a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and having a heterologous sequence inserted between the splice donor site and the splice acceptor site of the NS gene segment. The virus can be used as vector for expression of various proteins like chemokines, cytokines or antigenic structures and to produce vaccines. A fusion peptide comprising part of the N-terminus of an NS1 protein and a signal sequence fused to the C-terminus of said NS1 peptide is also provided. | 02-13-2014 |
20140038264 | METHOD OF PRODUCING A POLYPEPTIDE OR VIRUS OF INTEREST IN A CONTINUOUS CELL CULTURE - Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d | 02-06-2014 |
20140030284 | COMPOSITIONS COMPRISING CHIMERIC OSPA MOLECULES AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of | 01-30-2014 |
20140030252 | METHOD TO PRODUCE A HIGHLY CONCENTRATED IMMUNOGLOBULIN PREPARATION FOR SUBCUTANEOUS USE - The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described. | 01-30-2014 |
20140027380 | DIALYSIS SYSTEM HAVING AUTOIDENTIFICATION MECHANISM - A dialysis system is disclosed including an autoconnection mechanism. The autoconnection mechanism in an embodiment is configured such that (i) a tip protector remover is translated in a first direction towards a plurality of supply line connectors, (ii) the tip protector remover is locked to each of a plurality of supply line tip protectors connected to the plurality of supply line connectors, (iii) the tip protector remover is translated in a second direction away from the plurality of supply line connectors to remove the plurality of supply line tip protectors from the supply line connectors, the tip protector remover is translated in a third direction different from the first and second directions, and (v) solution line connectors are translated towards the supply line connectors to connect each of the solution line connectors to one of the supply line connectors. | 01-30-2014 |
20140024808 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 01-23-2014 |
20140021111 | DYNAMIC WEIGHT BALANCING OF FLOW IN KIDNEY FAILURE TREATMENT SYSTEMS - A kidney failure treatment system includes: (i) a dialysate supply; (ii) a weighing device; a control container coupled operably to the weighing device; (iii) a diffusion membrane; (iv) a drain; first and second pumps; (v) a first fluid conduit coupled fluidly to the dialysate supply and the diffusion membrane, the first fluid conduit coupled operably to the first pump; (vi) a second fluid conduit coupled fluidly to the control container and the drain, the second fluid conduit coupled operably to the first pump; and (vii) a third fluid conduit coupled fluidly to the diffusion membrane and the control conduit, the third fluid conduit coupled operably to the second pump. | 01-23-2014 |
20140014568 | MULTIZONE POLYMER MEMBRANE AND DIALYZER - Membranes are made from polymers and heat treated so that they have at least two zones with pores of different sizes. Pores with a smaller size have a lower molecular weight cut off than pores with a larger size. Zones with pores of different sizes may also be made by coating portions of membranes with polymer coatings. Membranes with pores of different sizes may be used in dialyzers for hemofiltration, hemodiafiltration, and other hemodialysis procedures. The membranes may also be used in other separation processes. | 01-16-2014 |
20130346102 | DIALYSIS TREATMENT PRESCRIPTION SYSTEM AND METHOD - A dialysis system includes: a home dialysis machine located at a patient's home; a clinician computer associated with a dialysis center, the dialysis center located remotely from the home dialysis machine; a server in data communication with the home dialysis machine and the clinician computer; and wherein the system is configured and arranged for (i) treatment data to be sent by the home dialysis machine to the clinician computer via the server, and (ii) the treatment data to be analyzed to form a treatment prescription that is delivered to and used by the home dialysis machine to perform a subsequent treatment. | 12-26-2013 |
20130346099 | NETWORKED DIALYSIS SYSTEM - A dialysis system includes (i) a first home dialysis machine located at a first patient's home; (ii) a second home dialysis machine located at a second patient's home; (iii) a first modem in data communication with the first home dialysis machine; (iv) a second modem in data communication with the second home dialysis machine; (v) a clinician server associated with a dialysis center; (vi) a first clinician computer in data communication with the clinician server; (vii) a second clinician computer in data communication with the clinician server; (viii) a dialysis center modem in data communication with the clinician server; and (ix) a network in data communication with the first modem, the second modem and the dialysis center modem. | 12-26-2013 |
20130345622 | REUSABLE EFFLUENT DRAIN CONTAINER WITH KEY FEATURE FOR DIALYSIS AND OTHER MEDICAL FLUID THERAPIES - A dialysis system includes a source of effluent dialysis fluid, a drain container configured to receive the effluent dialysis fluid through a drain tube, and a load cell. The drain container includes an at least semi-rigid body defining a first key feature. The load cell includes a second, mating key feature positioned and arranged to mate with the first key feature. | 12-26-2013 |
20130345621 | HYBRID BLOOD AND PERITONEAL DIALYSIS TREATMENT SYSTEMS AND METHODS - A method for a hybrid blood and peritoneal dialysis (“PD”) machine comprising: (i) determining whether a previous treatment left a last fill of dialysate in a patient's peritoneum; (ii) if a next treatment is a PD treatment, and if the previous treatment did not leave the last fill of dialysate, causing a PD treatment in which a first cycle is a fill cycle to be initiated; (iii) if the next treatment is a PD treatment, and if the previous treatment did leave the last fill of dialysate, causing a PD treatment in which a first cycle is a last fill drain cycle to be initiated; and (iv) if the next treatment is a blood treatment and if the previous treatment did leave the last fill of dialysate, causing a blood treatment including a last fill drain cycle to be initiated. | 12-26-2013 |
20130344535 | Virus Filtration of Cell Culture Media - The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m | 12-26-2013 |
20130334165 | PACKAGING SYSTEM AND METHODS OF ALERTING A PRACTITIONER - A packaging system includes a container having a closed end, an open end, a longitudinal axis running through the closed end and the open end, and an outer surface, a closure assembly fitted to the open end of the container and having an access port, and a detachable cap disposed over the access port. The system also includes a label disposed about the container, the label having a first region angled relative to the longitudinal axis, the first region consisting essentially of a name of a product. A method of alerting a practitioner to contents of a container is also provided. | 12-19-2013 |
20130334138 | DUAL, SINGLE NEEDLE BLOOD TREATMENT SYSTEM AND METHOD - A blood treatment system includes: (i) a dialysate circuit; (ii) a blood filter in fluid communication with the dialysate circuit; and (iii) an extracorporeal circuit in fluid communication with the blood filter, the extracorporeal circuit including a blood pump, a downstream line from the blood pump, an upstream line to the blood pump, a first patient access line, a second patient access line, a first valve arrangement fluidly communicating the first and second patient access lines to the downstream line, and a second valve arrangement fluidly communicating the first and second patient access lines to the upstream line. | 12-19-2013 |
20130334078 | ASSEMBLY TO FACILITATE USER RECONSTITUTION - A reconstitution assembly includes a housing including a lower sleeve and an upper sleeve, including a first container and a second container disposed vertically opposite the first container. A transfer set assembly is disposed within the housing between the first container and the second container. The transfer set assembly includes an upper spike housing and a lower spike housing, with a flow path defined through the upper spike housing and the lower spike housing. The transfer set assembly is configured to access contents of the first container and then upon the activation of a triggering mechanism, create a fluid pathway between the first container and the second container. The triggering mechanism ensures the transfer set assembly sequentially accesses the contents of the first container before accessing the contents of the second container. The disposition of the first container activates the triggering mechanism. | 12-19-2013 |
20130331775 | PERITONEAL DIALYSIS SYSTEMS AND METHODS HAVING GRAPHICAL USER INTERFACE - A peritoneal dialysis machine including a membrane pump and a touch screen display that includes a mode-indicating portion and an operation-descriptive portion, the mode-indicating portion having a plurality of touch sensitive indicia each indicating one of a plurality of modes in which the machine can operate, the display being used to keep a patient continually informed of which one mode of at least three operating modes the machine is operating in, as the operation-descriptive portion changes to display details of a specific operation being carried out within the one mode, the indicia for each of the three operating modes always being visible to the patient while the machine is operating, the operating mode being selected by the patient touching one of the indicia on the screen. | 12-12-2013 |
20130324915 | STEPPER MOTOR DRIVEN PERITONEAL DIALYSIS MACHINE - A peritoneal dialysis system includes: an enclosure including an actuation surface and a door; a stepper motor housed by the enclosure; a pump head and a solid pump piston structurally linking the pump head to the stepper motor; and a disposable unit accepted by the enclosure, the disposable unit including a flexible membrane attached to a rigid piece, the actuation surface of the enclosure and the disposable unit so configured and arranged that when the stepper motor turns and consequently translates the solid pump piston and the pump head towards the door, the pump head physically contacts and stretches the membrane from a relaxed position to a stretched position, and when the stepper motor turns and consequently translates the solid pump piston and the pump head away from the door, the membrane follows the pump head and transitions from the stretched position to the relaxed position. | 12-05-2013 |
20130324900 | SYSTEM AND METHOD FOR ACTIVE BYPASS DIALYSIS ACCESS DISCONNECTION DETECTION - A dialysis system comprising: a blood circuit including a blood pump, a dialyzer, and an air removal apparatus; an arterial line of the blood circuit extending from the blood pump to an arterial access needle; a venous line of the blood circuit extending from the air removal apparatus to a venous access needle; arterial and venous conductive connections placed along the arterial and venous lines, respectively; a first electrical potential source configured to apply a first electrical potential between (i) the arterial and venous conductive connections and (ii) the arterial and venous access needles; and a second electrical potential source configured to apply a second electrical potential between (a) the arterial and venous conductive connections and (b) one of the blood pump, dialyzer or air removal device. | 12-05-2013 |
20130323122 | CITRATE ANTICOAGULATION SYSTEM FOR EXTRACORPOREAL BLOOD TREATMENTS - A machine-readable medium with instructions for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream. | 12-05-2013 |
20130318640 | VITAMIN K EPOXIDE RECYCLING POLYPEPTIDE VKORC1, A THERAPEUTIC TARGET OF COUMARIN AND THEIR DERIVATIVES - The invention relates to a novel polypeptide vitamin K epoxide recycling polypeptide (VKORC1) as a target for coumarin and its derivatives. The invention further provides methods for identifying coumarin derivatives, and also claims VKORC1 polypeptides and VKORC1 nucleic acids containing a sequence abnormality associated with a VKORC1 associated deficiency such as warfarin resistance, wherein the VKORC1 polypeptides and VKORC1 nucleic acids can be used for diagnosing these deficiencies. Moreover, the invention relates to methods for identifying coumarin derivatives usable in pest control of rodents. | 11-28-2013 |
20130316434 | Animal Protein Free Media for Cultivation of Cells - The present invention relates to animal protein free cell culture media comprising a combination of non-animal derived peptides derived from soy hydrolysate and yeast hydrolysate. The invention also provides an animal protein free culture process, wherein cells are cultivated, propagated and passaged without animal-derived components. This process is useful for cultivating cells, such as recombinant cells or cells infected with a virus, and for production biological products by cell culture processes under conditions devoid of animal protein components. | 11-28-2013 |
20130313194 | METHOD OF OPTIMIZING CLEARANCE FOR PROTEIN-BOUND MOLECULES USING CASCADE FILTRATION THERAPY - A method of removing unwanted molecules from blood includes (i) directing a flow of blood from a patient through a first hemofilter, (ii) removing a volume of fluid from the blood using the first hemofilter, (iii) combining a volume of first substitution fluid with an outflow from the first hemofilter, the volume of first substitution fluid being substantially equal to the volume of fluid removed from the blood using the first hemofilter, (iv) directing the combined first hemofilter outflow and the first substitution fluid volume from the first hemofilter through a second hemofilter, (v) combining a second substitution fluid with outflow from the second hemofilter, and (vi) returning the combined second hemofilter outflow and the second substitution fluid volume from the second hemofilter to the patient. | 11-28-2013 |
20130310735 | SYSTEM AND METHOD FOR SELECTION OF STORED DIALYSIS THERAPY PRESCRIPTIONS - In an embodiment, an automated peritoneal dialysis (“APD”) machine includes at least one pump, a logic implementer storing a plurality of therapy prescriptions by which to operate the at least one pump, each therapy prescription pre-approved for a particular patient, and an input device operating with the logic implementer to allow the patient to select one of the therapy prescriptions for a particular therapy. In another embodiment, the input device operating with the logic implementer allows a doctor/clinician to select or approve one of the therapy prescriptions to be run on the APD machine. In a further embodiment, the logic implementer is programmed to select or suggest one of the therapy prescriptions to be run on the APD machine. | 11-21-2013 |
20130310726 | Home Medical Device Systems and Methods for Therapy Prescription and Tracking, Servicing and Inventory - A home medical device system includes a plurality of home therapy machines that perform a home therapy on a patient; a connectivity server; a system hub coupled to the home therapy machines through the connectivity server; a web portal configured to access the system hub; a plurality of clinics connected to the system hub via the web portal; and a website accessible via the web portal, the website including a patient portion available to patients using the plurality of home therapy machines, the website further including a clinician portion that enables the clinics to manage the home therapy machines. | 11-21-2013 |
20130303731 | MANUFACTURE OF FACTOR H (FH) AND FH-DERIVATIVES FROM PLASMA - The present invention provides compositions and pharmaceutical formulations of Factor H derived from plasma. Also provided are methods for the manufacture of the Factor H compositions and formulations, as well as methods for the treatment of diseases associated with Factor H dysfunction. | 11-14-2013 |
20130284735 | Packaging for Multiple Medical Containers - A system includes a first container having a wall defining a receptacle, a neck defining an opening, and a flip cap disposed over the opening, and a second container having a wall defining a receptacle, a neck defining an opening, and a flip cap disposed over the opening. The system also includes a carrier having first and second carrier pieces disposed about the first and second containers and attached together with the first and second containers secured therebetween. The system further includes a top cap attached to the flip caps to secure the first and second containers together and to simultaneously remove the flip caps from the containers. | 10-31-2013 |
20130274193 | TFPI INHIBITORS AND METHODS OF USE - The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject. | 10-17-2013 |
20130267584 | APTAMERS TO TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE AS BLEEDING DISORDER THERAPEUTICS - The present invention provides compositions and methods for modulating TFPI protein plasma concentration and TFPI protein function. Such modulation can be used to treat blood disorders such as bleeding disorders and clotting disorders. | 10-10-2013 |
20130252896 | TFPI INHIBITORS AND METHODS OF USE - The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound. | 09-26-2013 |
20130252263 | METHODS OF MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF - The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma. | 09-26-2013 |
20130248449 | FLUID AND AIR HANDLING IN BLOOD AND DIALYSIS CIRCUITS - An air purging method includes: (a) detecting a low fluid level in a blood circuit indicating a high amount of air in the blood circuit; (b) stopping a blood pump; (c) closing a venous patient line; (d) opening a blood circuit air vent valve and a drain valve; and (e) running the blood pump to meter air through the air vent valve and the drain valve to a drain. | 09-26-2013 |
20130248448 | Citrate-Based Dialysate Chemical Formulations - The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream. | 09-26-2013 |
20130231607 | DYNAMIC WEIGHT BALANCING OF FLOW IN KIDNEY FAILURE TREATMENT SYSTEMS - A kidney failure treatment system includes: (i) a dialysate supply; (ii) a weighing device; a control container coupled operably to the weighing device; (iii) a diffusion membrane; (iv) a drain; first and second pumps; (v) a first fluid conduit coupled fluidly to the dialysate supply and the diffusion membrane, the first fluid conduit coupled operably to the first pump; (vi) a second fluid conduit coupled fluidly to the control container and the drain, the second fluid conduit coupled operably to the first pump; and (vii) a third fluid conduit coupled fluidly to the diffusion membrane and the control conduit, the third fluid conduit coupled operably to the second pump. | 09-05-2013 |
20130230919 | ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS - The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes. | 09-05-2013 |
20130228517 | DYNAMIC WEIGHT BALANCING OF FLOW IN KIDNEY FAILURE TREATMENT SYSTEMS - A kidney failure treatment system includes: (i) a dialysate supply; (ii) a weighing device; a control container coupled operably to the weighing device; (iii) a diffusion membrane; (iv) a drain; first and second pumps; (v) a first fluid conduit coupled fluidly to the dialysate supply and the diffusion membrane, the first fluid conduit coupled operably to the first pump; (vi) a second fluid conduit coupled fluidly to the control container and the drain, the second fluid conduit coupled operably to the first pump; and (vii) a third fluid conduit coupled fluidly to the diffusion membrane and the control conduit, the third fluid conduit coupled operably to the second pump. | 09-05-2013 |
20130224184 | METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD - The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein. | 08-29-2013 |
20130224183 | FRACTION I-IV-1 PRECIPITATION OF IMMUNOGLOBINS FROM PLASMA - Among other aspects, the present invention provides methods for the manufacture of blood protein compositions from pooled plasma. In one embodiment, the invention provides an alcohol fractionation scheme that allows for significant increases in the yield of blood proteins purified from the starting plasma sample. In a specific embodiment, a method for fractionating pooled plasma is provided, the method comprising an initial low pH, high alcohol precipitation step. The present invention also provides pharmaceutical compositions of therapeutic blood proteins. | 08-29-2013 |
20130224150 | IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES - The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival. | 08-29-2013 |
20130216495 | PHARMACEUTICAL COMPOSITION COMPRISING CD34+ CELLS - The invention relates to the field of treatment of ischemic conditions and diseases using a cell population comprising CD34+ cells isolated from peripheral blood of a subject. The invention provides a pharmaceutical composition comprising (i) a cell population comprising CD34+ cells, (ii) a plasma protein, and (iii) an isotonic solution comprising at least one salt, said isotonic solution comprising acetate, gluconate, or both acetate and gluconate. Methods of treating tissue damaged by ischemia in a subject and methods of treating a medical condition, wherein the pharmaceutical composition of the invention is administered, are further provided herein. Also, methods of promoting mobilization of CD34+ cells from bone marrow into peripheral blood are provided herein. | 08-22-2013 |
20130213891 | METHOD AND COMPOSITION FOR REMOVING UREMIC TOXINS IN DIALYSIS PROCESSES - A dialysis system comprising: a sorbent cartridge in fluid communication with at least one of a patient or a dialyzer, the sorbent cartridge including a housing having a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; a storage container in fluid communication with the sorbent cartridge; a pump in fluid communication sorbent cartridge and the storage container; and a control unit in operable communication with the pump, wherein the control unit is programmed to cause the pump to pump a dialysis fluid to flow (i) in a first direction through the sorbent cartridge, wherein the zirconium phosphate layer is contacted by the dialysis fluid before the at least one of the urease layer, zirconium oxide layer or carbon layer and (ii) in a second direction, reverse from the first direction, through the sorbent cartridge wherein the at least one of the urease layer, zirconium oxide layer or carbon layer is contacted by the dialysis fluid before the zirconium phosphate layer. | 08-22-2013 |
20130209444 | NON-ANTICOAGULANT SULFATED OR SULFONATED POLYSACCHARIDES - The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process. | 08-15-2013 |
20130209370 | INJECTABLE VOID FILLER FOR SOFT TISSUE AUGMENTATION - The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition. | 08-15-2013 |
20130204192 | FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE - Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. | 08-08-2013 |
20130204173 | RENAL THERAPY BLOOD CLEANSING SYSTEM WITH ISOLATION FEATURE - A renal therapy blood cleansing system is provided. The renal therapy blood cleansing system includes a blood filtering device in fluid communication with a blood circuit, a balance chamber configured to exchange like volumes of fresh and used therapy fluid with the blood filtering device, a first pump configured to pump fresh fluid to the balance chamber, a second pump positioned and arranged to receive used fluid from the blood filtering device, and a control scheme. The control scheme is programmed to isolate the blood filtering device from the second pump and deliver a volume of fresh fluid to the blood filtering device via the balance chamber while the second pump is isolated from the blood filtering device, so as to increase fluid volume within the blood circuit. | 08-08-2013 |
20130202550 | NON-ANTICOAGULANT SULFATED OR SULFONATED SYNTHETIC POLYMERS - The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro. | 08-08-2013 |
20130201482 | OPTICAL IMAGING SYSTEM WITH MULTIPLE IMAGING CHANNEL OPTICAL SENSING - An optical imaging system for use with an infusion tube including: at least one light source for emitting at least two of first, second, or third spectrums of light; an optics system including a single lens for receiving and transmitting at least two of the first spectrum light transmitted through a first portion of the chamber, the second spectrum light transmitted through a second portion of the chamber, or the third spectrum light transmitted through a third portion of the chamber. The system includes a sensor receiving the at least two of the spectrums from the lens and generating and transmitting data characterizing the at least two of the spectrums. The system includes a memory element storing computer readable instructions and a processor to execute the instructions to generate, using the data, at least two of first, second, or third images of the first, second, and third portions, respectively. | 08-08-2013 |
20130197203 | Modified Polysaccharides for Conjugate Vaccines - The present invention relates to methods of manufacture of immunogenic glycoconjugates, in particular for use in pharmaceutical compositions for inducing a therapeutic immune response in a subject. The immunogenic glycoconjugates of the invention comprise one or more oligosaccharides or polysaccharides that are conjugated to one or more carrier proteins via an active aldehyde group. Accordingly, the invention provides methods of making (i) unsaturated microbial N-acyl derivative oligosaccharides or polysaccharides; (ii) novel conjugates of unsaturated N-acyl derivatives; and (iii) glycoconjugate compositions comprising conjugate molecules of fragments of microbial unsaturated N-acyl derivatives that serve as a covalent linker to one or more proteins. The invention further encompasses the use of the immunogenic glycoconjugates pharmaceutical compositions for the prevention or treatment of an infectious disease. | 08-01-2013 |
20130195897 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content. | 08-01-2013 |
20130193073 | BALANCED FLOW DIALYSIS MACHINE - A system and method for balancing flows of renal replacement fluid is disclosed. The method uses pressure controls and pressure sensing devices to more precisely meter and balance the flow of fresh dialysate and spent dialysate. The balancing system may use one or two balancing devices, such as a balance tube, a tortuous path, or a balance chamber. | 08-01-2013 |
20130193041 | CONTROL OF A WATER DEVICE VIA A DIALYSIS MACHINE USER INTERFACE - A home medical device system includes a home therapy machine for performing a home therapy on a patient; a user interface operably connected to the home therapy machine, the user interface receiving operator inputs; a water treatment device in fluid communication with the home therapy machine; and a data connection between the home therapy machine and the water treatment device, wherein the home therapy machine transmits data via the connection to the water treatment device for control of the water treatment device, the data provided based on at least one of the operator inputs received via the user interface. | 08-01-2013 |
20130190242 | Polymer-Von Willebrand Factor-Conjugates - The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF. | 07-25-2013 |
20130189678 | MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) PROMOTER POLYMORPHISM IN INFLAMMATORY DISEASE - Describe herein is a novel CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays. Four genotypes are described which comprise 5, 6, 7, or 8-CATT repeat units. Of these, the 5-CATT allele has the lowest level of basal and stimulated MIF promoter activity in vitro. The presence of the low expressing, 5-CATT repeat allele correlated with low disease severity in a cohort of rheumatoid arthritis patients. Methods, compositions and apparatus for detecting this CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif gene, and for using same for assessing predisposition to severe inflammatory disease, are also disclosed. | 07-25-2013 |
20130186828 | METHOD FOR POWERING PORTABLE DIALYSIS MACHINE - A method for operating a medical fluid machine, the method comprising: (i) if alternating current (“AC”) power is available, charging a battery, if needed, and powering the medical fluid machine with the AC power; and (ii) if AC power is not available (a) if fuel cell power is available, charging the battery, if needed, and powering the medical fluid machine with the fuel cell power; and (b) if fuel cell power is not available, powering the medical fluid machine using battery power until the AC power or fuel cell power is available. | 07-25-2013 |
20130186759 | HEMODIALYSIS AND PERITONEAL DIALYSIS SYSTEMS HAVING ELECTRODIALYSIS AND ELECTRODEIONIZATION CAPABILITIES - Systems and methods for hemodialysis or peritoneal dialysis having integrated electrodialysis and electrodeionization capabilities are provided. In an embodiment, the dialysis system includes a carbon source, a urease source, an ED/EDI unit. The carbon source, urease source, and/or the ED/EDI unit can be in the form of removable cartridges. | 07-25-2013 |
20130177933 | Characterization of Subvisible Particles Using a Particle Analyzer - The present specification discloses methods of characterizing a population of particles using a particle analyzer. Particles may be characterized by size, absolute number, whether the particle is non-proteinaceous or proteinaceous, whether a proteinaceous particle has or lacks a certain physical property, or any combination thereof. | 07-11-2013 |
20130177601 | AQUEOUS COMPOSITIONS AND METHODS FOR BONE HEMOSTASIS - Bone hemostat compositions, and methods for their use and manufacture are provided. Exemplary hemostatic compositions include polymeric components such as random and non-random copolymers, natural polymers, ceramics, reactive group polymers, and combinations thereof. Bone compositions may be used during surgical procedures, and may be applied to bone to inhibit or prevent bleeding from bone. | 07-11-2013 |
20130175235 | PHARMACEUTICAL PRODUCT WITH CLOSURE ASSEMBLY - A system includes a container and an adapter. The container may include a wall defining a receptacle and a neck, the neck forming an opening and a passage in fluid communication between the receptacle and the opening; a closure assembly having a portion disposed within the neck, and including an insert defining a valve seat, an actuator, a valve member attached to the actuator and sealingly engageable with the valve seat, and a biasing member disposed between the insert and the actuator. The biasing member urges the valve member into sealing engagement with the valve seat in an actuator advanced state, and the valve member disengages from the valve seat in an actuator retracted state, the actuator depending through the opening in the advanced state. The adapter may be removably attached to the container, and configured to move the actuator from advanced to retracted state upon attachment. | 07-11-2013 |
20130172269 | LYOPHILIZED RECOMBINANT VWF FORMULATIONS - The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations. | 07-04-2013 |
20130158521 | Medical Tubing Connection Assembly - A medical tubing connector pair includes a female tubing connector, and a male tubing connector. The female tubing connector has an external thread and the male tubing connector has an internal thread, the external and internal threads threadingly engaged to secure the female and male tubing connectors together. The internal thread is made from a flexible material to permit the female and male tubing connectors to be connected to or disconnected from each other without rotation of the tubing connectors relative to each other. | 06-20-2013 |
20130158469 | DIALYSIS MACHINE WITH ELECTRICAL INSULATION FOR VARIABLE VOLTAGE INPUT - A dialysis machine includes: a source of dialysis solution; a pump configured to pump the dialysis solution; a heater configured to heat the dialysis solution; an electrical input receiving power from a remote power source; and a housing supporting the pump, the heater and the electrical input, the housing including an electrical insulation rated for 240 VAC such that the remote power source can be either 110 or 240 VAC. | 06-20-2013 |
20130153495 | SYSTEMS AND METHODS FOR PRIMING SORBENT-BASED HEMODIALYSIS USING DIALYSIS FLUID - A method for priming a hemodialysis treatment includes: providing a sorbent cartridge for cleaning spent dialysate fluid returning from a dialyzer; preparing a batch of dialysate in a quantity commensurate with being recycled through the sorbent cartridge multiple times; priming a dialysate circuit in fluid communication with the dialyzer using the batch of dialysate; and priming a blood circuit in fluid communication with the dialyzer using the batch of dialysate. | 06-20-2013 |
20130153478 | DIALYSIS SYSTEM INCLUDING PERISTALTIC TUBING PUMPING CASSETTE - A hemodialysis system includes: a peristaltic blood pump; a first peristaltic dialysate pump; a second peristaltic dialysate pump; and a fluid cassette including an upper portion and a lower portion, a blood pumping tube extending linearly from the upper portion to the lower portion, the blood pumping tube actuated by the peristaltic blood pump, a first dialysate pumping tube extending linearly from the upper portion to the lower portion, the first dialysate pumping tube actuated by the first dialysate pump, and a second dialysate pumping tube extending linearly from the upper portion to the lower portion, the second dialysate pumping tube actuated by the second dialysate pump. | 06-20-2013 |
20130150557 | METHOD FOR THE PURIFICATION OF RECOMBINANT BLOOD COAGULATION FACTOR IX ENRICHED IN SULFATED AND/OR PHOSPHORYLATED MOLECULES - The present invention relates to a method for the purification of rFIX using anion exchange chromatography in the pseudo-affinity mode, wherein said method comprises a wash step with a wash buffer having a salt concentration of more than 200 mM. The purification according to the invention provides a method to enrich rFIX molecules which have been posttranslationally modified by sulfation and/or phosphorylation. The present invention further relates to purified rFIX compositions enriched in monosulfated and/or monophosphorylated rFIX molecules. | 06-13-2013 |
20130149740 | METHOD FOR THE PRODUCTION OF A POLYMERIZED PRODUCT - The invention discloses a method for the production of a polymerized product comprising the following steps:
| 06-13-2013 |
20130149700 | MEASUREMENT OF AUTOANTIBODIES AT LOW CONDUCTIVITY WITH INCREASED SENSITIVITY - Methods for detecting or capturing low-avidity autoantibodies in a biological sample are provided. Target antigen used to assay for the low-avidity autoantibodies of interest is immobilized on a solid phase. The biological sample is contacted under low conductivity condition with the target antigen for which the autoantibodies has specific binding affinity. Binding of the target antigen to the autoantibodies of interest in the biological sample is then detected to ascertain the presence or concentration of the autoantibodies of interest. | 06-13-2013 |
20130143808 | Fibrin Gel for Controlled Release of PDGF and Uses Thereof - The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases. | 06-06-2013 |
20130143238 | PROCEDURE FOR THE GENERATION OF A HIGH PRODUCER CELL LINE FOR THE EXPRESSION OF A RECOMBINANT ANTI-CD34 ANTIBODY - The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines. | 06-06-2013 |
20130138037 | MEDICAL FLUID MACHINE WITH SUPPLY AUTOCONNECTION - A medical fluid system including: fluid containers and a tube extending from same, each tube including a cap; a pumping cassette including port spikes; a medical fluid machine including: occluders; a shuttle configured to receive the tubes, wherein each tube is associated with one of the occluders; a driving mechanism translating the shuttle; a cap removal device between the cassette and the shuttle; and a control unit programmed to cause: (i) the occluders to pinch their tubes, (ii) cause the driving mechanism to translate the shuttle towards the fluid pumping cassette, the cap removal device engaging the tube caps, (iii) the driving mechanism to translate the shuttle away from the fluid pumping cassette and cap removal device, pulling the tube caps off of the tubes, and (iv) the driving mechanism to translate the shuttle back towards the fluid pumping cassette for the port spikes to spike the occluded tubes. | 05-30-2013 |
20130136732 | ADAMTS13-CONTAINING COMPOSITIONS HAVING THROMBOLYTIC ACTIVITY - This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof. | 05-30-2013 |
20130131583 | TRANSFER SETS FOR THERAPY OPTIMIZATION - Transfer sets are disclosed in the present patent. The transfer set provides a connection between a source of peritoneal dialysis fluid and a patient for whom peritoneal dialysis has been prescribed. The transfer sets disclosed herein are smaller and provide a more compact and convenient device by which a dialysis patient controls the flow of dialysis fluid to and from the peritoneum of the patient. The devices are more compact and convenient because they include more convenient mechanisms for starting and stopping flow of the dialysis fluid. It is also easy to determine whether the mechanism is in a closed or open configuration by simply looking at the mechanism. | 05-23-2013 |
20130131581 | METHOD OF OPERATING A DIPSOSABLE PUMPING UNIT - A method of operating a disposable pumping unit includes enabling the disposable pumping unit to be loaded into a peritoneal dialysis hardware unit between a door and a housing of the hardware unit; structuring the disposable pumping unit to have a fluid pump receptacle, the fluid pump receptacle constructed and arranged to extend from both surfaces of the unit so as to fit within a first opening provided in the door and a second opening provided in the housing of the hardware unit; and enabling the disposable pumping unit to be guided into the hardware unit such that the fluid pump receptacle becomes aligned with the opposing first and second openings when the door is closed against the housing. | 05-23-2013 |
20130129710 | HEMOSTATIC COMPOSITIONS - The invention discloses a method for producing a hemostatic composition comprising mixing a biocompatible polymer suitable for use in hemostasis and a genipin-type crosslinker, crosslinking said polymer by said genipin-type crosslinker to obtain a crosslinked biocompatible polymer, and finishing said crosslinks polymer to a pharmaceutically acceptable hemostatic composition, new hemostatic compositions and methods for using such compositions. | 05-23-2013 |
20130125808 | DEVICE TO INDICATE PRIMING OF AN INFUSION LINE - A priming indicator for a fluid infusion system includes a luer cap or other component of the infusion system having an indicator surface covered by a membrane. The membrane exhibits a first visual characteristic, such as being opaque, when dry and exhibits a second characteristic, such as becoming less opaque, when wet. Once the membrane becomes wet, indicia on the surface, which may be provided on a rod at least partially covered by the membrane, becomes visible, thereby indicating an intravenous tube to which the luer cap is secured has been primed or is nearly primed. The indicator may alternately be employed at an upstream end of an infusion set, such as at the port of a medical bag providing a supply of fluid, to indicate a low level of fluid in the medical bag. | 05-23-2013 |
20130123745 | INFUSION PUMP INCLUDING PAIN CONTROLLED ANALGESIC ("PCA") APPARATUS - An infusion pump includes: a housing, a pump actuator supported by the housing, electronics configured to control the pump actuator, a pain controlled analgesic (“PCA”) input device, a cord having a remote end connected to the PCA input device and a local end connected to the housing, a remote integrated circuit; and a local integrated circuit in communication with the electronics and the remote integrated circuit so as to provide operational information concerning the PCA input device to the electronics. | 05-16-2013 |
20130115204 | PREPARATIVE PURIFICATION PROCESS FOR HUMAN FURIN - Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC™ resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC™ chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%. | 05-09-2013 |
20130101579 | METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD - The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein. | 04-25-2013 |
20130096481 | SYSTEMS AND METHODS FOR OPTICAL ACCESS DISCONNECTION - An access disconnection system includes: a material capable of absorbing blood from a patient, a light emitter positioned to emit light onto a first portion of the material, the first portion spaced at least a threshold distance from a second portion of the material, the second portion located so as to cover arterial line and venous line access points to the patient, the threshold distance including a distance from the access points to provide for an allowable amount of blood seepage from either access point due to a needle stick, a receiver positioned adjacent to the light emitter to receive light reflected off of the first portion of the material, and circuitry coupled to the light emitter and receiver and configured to provide an output (i) when light received by the receiver reaches a particular level or (ii) indicative of an amount of light received by the receiver. | 04-18-2013 |
20130096480 | ACCESS DISCONNECTION SYSTEMS WITH ARTERIAL AND VENOUS LINE CONDUCTIVE PATHWAY - An extracorporeal blood system includes: an extracorporeal blood machine; an arterial line extending from the extracorporeal blood machine; a venous line extending from the extracorporeal blood machine; and an access disconnection circuit for detecting a disconnection of at least one of the arterial or venous lines from a patient, the access disconnection circuit including (i) a signal generation source having first and second signal generation source electrical lines each in electrical communication with blood traveling through one of the arterial or venous lines, (ii) a conductive pathway electrically communicating blood traveling through the arterial line with blood traveling through the venous line, and (iii) a signal processing unit positioned and arranged to process a signal generated by the source to detect the disconnection of the at least one of the arterial and venous lines. | 04-18-2013 |
20130096082 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition composing chitin or a water insoluble chitin derivative, especially water insoluble chitosan, in particulate form, wherein the composition is present in paste form. | 04-18-2013 |
20130096063 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition comprising:
| 04-18-2013 |
20130096062 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition comprising:
| 04-18-2013 |
20130090291 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition comprising:
| 04-11-2013 |
20130079710 | Therapy Management Development Platform - A therapy management development platform includes a pump controller coupled to an interface module. The interface module includes an interface module controller and a module-sensor input/output interface including at least one standardized input port, output port and power connection. The interface module is also customizably programmed to receive data from a sensor and to provide instructions to the pump controller to vary the operation of a pump coupled thereto according to one of a plurality of levels of functionality. Upon receipt of an indication of approval from a remote computer to change the level of access to the functionality of the platform, the interface module may be customizably programmed to receive different data from the sensor, to provide different instructions to the pump controller, or both, the approval corresponding to a stage in testing of a medical device. | 03-28-2013 |
20130079706 | DIALYSIS SYSTEM HAVING DISPOSABLE CASSETTE - A dialysis system includes a dialysis instrument and a disposable cassette. The dialysis instrument includes three pump actuators. The disposable cassette includes three dialysate pump chambers. The three dialysate pump chambers are positioned and arranged to operate with the three dialysate pump actuators of the dialysis instrument. | 03-28-2013 |
20130079705 | METHOD FOR MONITORING AND CONTROLLING PERITONEAL DIALYSIS - A dialysis apparatus includes a housing; a first electrical contact carried by the housing; a hydrogel material located within the housing; a second electrical contact connected to the hydrogel material, the hydrogel material located so as to be contacted by a liquid flowing through the housing; and wherein the hydrogel material expands as the material absorbs the liquid such that the second electrical contact is moved and eventually engage the first electrical contact. | 03-28-2013 |
20130078264 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content. | 03-28-2013 |
20130078261 | ENVELOPED VIRUS VACCINE AND METHOD FOR PRODUCTION - The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen. | 03-28-2013 |
20130071906 | CELL CULTURE MEDIUM FOR ADAMTS PROTEIN EXPRESSION - The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein. | 03-21-2013 |
20130058961 | METHOD FOR REDUCING THE THROMBOEMBOLIC POTENTIAL OF A PLASMA-DERIVED IMMUNOGLOBULIN COMPOSITION - The present invention provides methods for reducing the amidolytic and anti-complement activity (ACA) content of an immunoglobulin composition through the use of cation exchange chromatography. In a specific embodiment, the invention provides methods for reducing the Factor XI and/or Factor XIa and/or ACA content of an immunoglobulin composition by collecting the leading portion of a cation exchange eluate. The present invention also provides immunoglobulin composition having reduced levels of amidolytic activity, Factor XI, and/or Factor XIa, and/or ACA content. | 03-07-2013 |
20130052672 | KIT FOR MEASURING THE THROMBIN GENERATION IN A SAMPLE OF A SAMPLE OF A PATIENT'S BLOOD OR PLASMA - The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl | 02-28-2013 |
20130052188 | SYSTEMS AND METHODS FOR OBTAINING IMMUNOGLOBULIN FROM BLOOD - The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component of the blood including immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; and a second conduit configured to convey at least a portion of the second component of the blood from the first conduit to the donor. | 02-28-2013 |
20130046117 | PROCESS FOR THE MANUFACTURING OF SEVOFLURANE - The present invention provides a method for forming sevoflurane comprising (i) combining chlorosevo ether, a nucleophilic fluoride reagent, and a solvent comprising sevoflurane to form an initial reaction mixture and (ii) reacting the initial reaction mixture to form additional sevoflurane relative to the amount of sevoflurane present in the initial reaction mixture. The present disclosure is also directed to a method for forming sevoflurane, comprising: initiating a reaction between chlorosevo ether and a nucleophilic fluoride reagent in an initial reaction mixture further comprising a solvent comprising sevoflurane, thereby forming additional sevoflurane relative to the amount of sevoflurane present in the initial reaction mixture. | 02-21-2013 |
20130037461 | CUSTOMIZABLE PERSONAL DIALYSIS DEVICE HAVING EASE OF USE AND THERAPY ENHANCEMENT FEATURES - A peritoneal dialysis machine includes an enclosure; dialysate pump located within the enclosure; a graphical user interface allowing a patient to program a treatment including at least one patient fill performed by the dialysate pump, at least one dwell, and at least one drain performed by the dialysate pump; and the GUI further programmed to provide an alert when it is time to begin the treatment so as to complete the at least one patient fill, dwell and drain by a prescribed time. | 02-14-2013 |
20130030357 | SYSTEM AND METHOD FOR PAIRING A DIALYSIS MACHINE WITH PERIPHERAL DEVICES - A dialysis system includes: a dialysis machine; and at least one of a blood pressure sensor and a weight sensor in wireless communication with the dialysis machine, wherein the dialysis machine is so positioned and arranged relative to the at least one blood pressure sensor or weight sensor that the dialysis machine is discoverable by the at least one blood pressure sensor or weight sensor when the at least one blood pressure sensor or weight sensor, respectively, is powered, and such that the at least one blood pressure sensor or weight sensor becomes paired automatically with the dialysis machine for secure wireless communication. | 01-31-2013 |
20130030356 | SODIUM MANAGEMENT FOR DIALYSIS SYSTEMS - Systems and methods for providing dialysis therapies are provided. In a general embodiment, the present disclosure provides an apparatus for dialysis treatment comprising first and second fluid flow pathways in a parallel arrangement. The first fluid flow pathway contains a first cation exchange resin, wherein greater than 90% of exchange sites of the first cation exchange resin are populated with hydrogen ions. The second fluid flow pathway contains a second cation exchange resin, wherein greater than 90% of exchange sites of the second cation exchange resin are populated with sodium ions. The apparatus can be used to maintain a constant and safe level of sodium in a constantly regenerated dialysis fluid over an extended period of time. | 01-31-2013 |
20130028975 | HEMOSTATIC SPONGE - The present invention provides a hemostatic porous composite sponge comprising i) a matrix of a biomaterial and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that—said polymeric component is coated onto a surface of said matrix of a biomaterial, or—said matrix is impregnated with said polymeric material, or—both. | 01-31-2013 |
20130012442 | VON WILLEBRAND FACTOR- AND FACTOR VIII-POLYMER CONJUGATES HAVING A RELEASABLE LINKAGE - The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided. | 01-10-2013 |
20130011900 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE - The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst. | 01-10-2013 |
20130011387 | SYSTEMS AND METHODS FOR OBTAINING IMMUNOGLOBULIN FROM BLOOD - The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component of the blood including immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; and a second conduit configured to convey at least a portion of the second component of the blood from the first conduit to the donor. | 01-10-2013 |
20130008441 | ADAPTERS FOR USE WITH AN ANESTHETIC VAPORIZER - Adapters are provided for establishing fluid communication between an anesthetic agent container and an anesthetic vaporizer having a fluid port. The adapter may be mountable on the vaporizer to cooperate with the spout of an anesthetic agent container or may be mountable on an anesthetic agent container to cooperate with the fluid port of an anesthetic vaporizer to provide a sealing and/or retaining relationship therebetween. | 01-10-2013 |
20120329128 | FORMULATIONS OF RECOMBINANT FURIN - The present application provides stabilized formulations of furin (e.g., rfurin) containing a sugar, sugar alcohol, and/or non-ionic surfactant. As compared to non-stabilized compositions, the furin formulations disclosed herein retain greater amounts of furin activity and monomeric furin content, while reducing furin aggregation when stored and/or subjected to mechanical stress. Also provided are methods for stably diluting furin (e.g., rfurin) compositions. | 12-27-2012 |
20120329127 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME - The present disclosure relates to materials and methods of conjugating a water soluble polymer to a therapeutic protein. | 12-27-2012 |
20120328649 | Recombinant Viral Vectors and Methods for Inducing an Immune Response to Yellow Fever Virus - The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to yellow fever virus. The invention provides recombinant viral vectors based on the non-replicating modified vaccinia virus Ankara or based on a D4R-defective vaccinia virus. When administered according to methods of the invention, the recombinant viral vectors induce a broad immune response to yellow fever virus and demonstrate an excellent safety profile. | 12-27-2012 |
20120322737 | MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE - The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention. | 12-20-2012 |
20120322090 | SOLID PHASE-BOUND ELASTASE-BINDING ASSAY FOR THE MEASUREMENT OF ALPHA1-ANTITRYPSIN ACTIVITY - The present invention relates to a method for the measurement of active alpha | 12-20-2012 |
20120316116 | TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF - The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII. | 12-13-2012 |
20120316113 | FGF BASED FIBRIN BINDING PEPTIDES - The present invention relates to a polypeptide fragments of Fibroblast Growth Factor 2, wherein said fragments are adapted to bind to fibrinogen or to fibrin and/or increase cell proliferation, differentiation or migration. These fragments are suitable for promoting wound healing and/or hemostasis. | 12-13-2012 |
20120315650 | DETECTION OF CIRCULATING ADAMTS13-ANTIBODY COMPLEXES - The present invention relates to methods and means for detecting ADAMTS13 immune complexes in a sample. The methods include the steps of capturing and labelling immune complexes of anti-ADAMTS13 antibodies. Capturing and labelling may be achieved by two different binding units targeting the immune complexes. The invention further relates to diagnosing diseases associated with immunologic ADAMTS13 dysfunction like TTP (thrombotic thrombocytopenic purpura). | 12-13-2012 |
20120310204 | Method and System for Alerting as to Potential for Bolus Condition - A method of alerting a user to a potential unintended bolus delivery includes delivering fluid to a patient along a first fluid flow path. The method also includes transmitting a signal prior to initiation of a change in fluid delivery to the patient along a second fluid flow path connected to the first fluid flow path upstream of the patient, and detecting the signal. The method further includes actuating an alarm to alert the user to a potential unintended bolus delivery if the signal is detected. A system for carrying out the method is also provided. | 12-06-2012 |
20120302637 | Methods of Treating Tachycardia and/or Controlling Heart Rate While Minimizing and/or Controlling Hypotension - A method of treating tachycardia while minimizing and/or controlling hypotension associated with such treatment includes administering a therapeutically effective amount of a pharmaceutical composition comprising the S-isomer of esmolol to a subject in need thereof. | 11-29-2012 |
20120296279 | ACCESS DISCONNECTION METHOD USING OPTICAL AND OTHER SENSORS - A method for detecting movement or disconnection of a needle at an access site of a patient comprising: sensing for a presence of blood at the access site while a medical procedure is performed on the patient; separately sensing for a movement of (i) the needle or (ii) tubing connected to the needle; and sending a signal indicating movement or disconnection of the needle if one of (a) the presence of blood is sensed or (b) movement is sensed under (i) or (ii). | 11-22-2012 |
20120296267 | DIALYSIS SYSTEM AND MACHINE HAVING THERAPY PRESCRIPTION RECALL - In an embodiment, an automated peritoneal dialysis (“APD”) machine includes at least one pump, a logic implementer storing a plurality of therapy prescriptions by which to operate the at least one pump, each therapy prescription pre-approved for a particular patient, and an input device operating with the logic implementer to allow the patient to select one of the therapy prescriptions for a particular therapy. In another embodiment, the input device operating with the logic implementer allows a doctor/clinician to select or approve one of the therapy prescriptions to be run on the APD machine. In a further embodiment, the logic implementer is programmed to select or suggest one of the therapy prescriptions to be run on the APD machine. | 11-22-2012 |
20120291875 | Citrate-Based Dialysate Chemical Formulations - The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream. | 11-22-2012 |
20120283629 | PERITONEAL DIALYSIS SYSTEM HAVING HEATER PAN AND WEIGHT SENSOR - A peritoneal dialysis machine includes: (i) a housing; (ii) an actuator carried by the housing so as to be able to interact with a peritoneal dialysis fluid carrying disposable; (iii) at least one heating element carried by the housing; (iv) a heater pan providing an upper surface of the housing, the heater pan cooperating with the at least one heater element to provide heat to a container of peritoneal dialysis fluid placed onto the heater pan, the container being part of or in communication with the peritoneal dialysis fluid carrying disposable; and (iv) a weight sensor cooperating with the heater pan to sense the weight of the peritoneal dialysis fluid located within the container. | 11-08-2012 |
20120277715 | PACKAGING ASSEMBLY TO PRVENT PREMATURE ACTIVATION - A package assembly for a drug reconstitution assembly includes a body, a drug reconstitution assembly and a removable lid. The body includes a plurality of protrusions configured to mate with a plurality of corresponding features of the drug reconstitution assembly to inhibit axial and rotational translation of the drug reconstitution assembly and its constituent parts during shipping and handling. By preventing axial and rotational shifting during shipment, premature and accidental puncture or contamination of the medication or the spikes within the drug reconstitution assembly is minimized. | 11-01-2012 |
20120277309 | METHODS OF CONTROLLING VENOUS IRRITATION ASSOCIATED WITH THE TREATMENT OF A CARDIAC DISORDER - A pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate in a concentration between about 75 mM and about 150 mM, which is substantially free of the R-isomer or pharmaceutically acceptable salt thereof, is provided. A method of treating a cardiac disorder is also provided and includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride, wherein the (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride is present at a concentration between about 75 mM and about 150 mM and wherein the pharmaceutical composition is substantially free of (R)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate or pharmaceutically acceptable salt thereof. | 11-01-2012 |
20120271273 | MEDICAL FLUID AUTOCONNECTION AND AUTOIDENTIFICATION METHOD - A medical fluid autoconnection method includes: enabling acceptance a pierceable connector that is capable of fluidly communicating with a source of medical fluid into a moveable holder; temporarily fixing a spike to a medical fluid pumping machine; automatically detecting whether the pierceable connector has been placed into the moveable holder; if the pierceable connector is sensed as being placed in the moveable holder, moving the holder so that the spike pierces the pierceable connector; and enabling medical fluid to be pumped from the source through the connected spiked and connector. | 10-25-2012 |
20120270255 | METHODS FOR ISOLATING AND QUANTIFYING ANTIGEN FROM VACCINES - The disclosure relates to the development of improved methods for quantifying antigen in a vaccine composition in the absence of available antigen standards. More specifically, the disclosure provides fast and robust methods of separating antigens from vaccine compositions, comprising the steps of solubilizing antigen without detergent and without alkylation, using acidification to prevent antigen subtypes from binding again, isolating antigen subtypes with chromatography, and quantifying the eluted antigen with amino acid analysis. The methods of the disclosure are applicable for use with a variety of antigens, thereby providing an improved method in the art of vaccine manufacturing to date. | 10-25-2012 |
20120265115 | ACOUSTIC ACCESS DISCONNECTION SYSTEMS AND METHODS - An access disconnection method includes supporting a transmitter including a wireless communication apparatus, a receiver, a portion of an arterial line, a portion of a venous line and electronic circuitry by a member separate from a blood treatment machine. The method further includes operably communicating the electronic circuitry with the transmitter and the receiver, enabling transmission of a wave from the transmitter in one of the arterial and venous lines, enabling receipt of the wave by the receiver in the other of the arterial and venous lines, and enabling a disconnection output to be sent to the blood treatment machine via the electronic circuitry. The disconnection output is indicative of a change in the wave received by the receiver from the transmitter sufficient to expect that an access site disconnection of one of the arterial and venous lines has occurred. | 10-18-2012 |
20120259276 | PUMPING SYSTEMS FOR CASSETTE-BASED DIALYSIS - A dialysis machine includes: a hardware unit including at least one pump actuator, at least one valve actuator and a cassette interface, the cassette interface including: (i) a plate that abuts the cassette; (ii) at least one pump aperture defined by the plate; (iii) at least one pump head moveable out of and retractable into the at least one pump aperture to operate a pumping portion of the cassette; (iv) at least one valve aperture defined by the plate; (v) at least one valve apparatus moveable out of and retractable into the at least one valve aperture to operate a valve portion of the cassette; (vi) at least one sensor aperture defined by the plate; and (vii) at least one sensor located in the least one sensor aperture, the at least one sensor operable with a sensor portion of the cassette. | 10-11-2012 |
20120251524 | USE OF CYTOKINE LEVELS IN INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to the use of the level of certain cytokines in a patient's blood as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiveness of a treatment regimen. Methods for treating Alzheimer's disease and monitoring therapeutic effectiveness are provided. | 10-04-2012 |
20120248039 | DIALYSIS SYSTEM INCLUDING MULTI-HEATER POWER COORDINATION - A dialysis system includes a first fluid heater, a second fluid heater, a supplemental power source and a logic implementer. The logic implementer is configured to use the supplemental power source such that when the first and second heaters are powered simultaneously, a collective current draw does not exceed a maximum allowable current draw of a branch power source powering the system | 10-04-2012 |
20120241367 | DIALYSIS SYSTEM HAVING AUTOCONNECTION - A dialysis system includes a dialysis machine including at least one fluid pump, and an autoconnection mechanism including a moveable holder; a plurality of pierceable connectors each held by the moveable holder of the autoconnection mechanism, each of the pierceable connectors in fluid communication with a source of medical fluid; a plurality of spikes each held fixed by the dialysis machine, each of the spikes in fluid communication with a disposable component that is positioned and arranged to operate with the at least one fluid pump; and wherein the moveable holder is moved automatically by the autoconnection mechanism, so that (i) the spikes pierce the pierceable connectors and (ii) the sources of medical fluid can communicate with the disposable component positioned and arranged to operate with the at least one fluid pump. | 09-27-2012 |
20120238525 | PERITONEAL DIALYSIS SOLUTIONS COMPRISING GLUCOSE POLYMERS - Peritoneal dialysis solutions including a glucose polymer and methods of using the dialysis solutions are disclosed herein. In a general embodiment, the peritoneal dialysis solution includes a glucose polymer in an amount to provide an increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed compared to conventional dialysis solutions containing icodextrin as the active pharmaceutical ingredient. The increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed is obtained by providing specific combinations of weight-average molecular weight, polydispersity index and concentration of the glucose polymer in the dialysis solution. | 09-20-2012 |
20120232471 | NON-INVASIVE RADIO FREQUENCY MEDICAL FLUID LEVEL AND VOLUME DETECTION SYSTEM AND METHOD - A medical fluid system includes a medical fluid pump; a container holding a fluid to be pumped by the medical fluid pump, the fluid at a first time having a first conductivity, the fluid at a second time having a second conductivity; and a radio frequency level sensor positioned in operable relation with the container, the radio frequency operation of the level sensor configured so as to be (i) indicative of a level of the fluid in the container and (ii) at least substantially independent of whether the fluid has the first conductivity or the second conductivity. The medical fluid system can determine the level of medical fluid by measuring the resistance, impedance or phase shift seen by the sensor. | 09-13-2012 |
20120232252 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 09-13-2012 |
20120230872 | SYSTEMS AND METHODS FOR OBTAINING IMMUNOGLOBULIN FROM BLOOD - The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component of the blood including immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; and a second conduit configured to convey at least a portion of the second component of the blood from the first conduit to the donor. | 09-13-2012 |